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Abstract 
This study describes hydroxyurea use among children ages 1-17 with sickle cell anemia 
(SCA) enrolled in at least one year of Medicaid in 6 states from 2005-2012. Administrative 
claims were used to summarize the number of days’ supply of hydroxyurea dispensed by 
state and year. A total of 7,963 children with SCA contributed 22,424 person-years. Among 
person-years with at least 30 days of hydroxyurea, only 18% received at least than 300 days 
of hydroxyurea, which varied by state. Following updated recommendations for all children 
with SCA to begin hydroxyurea, strategies to increase hydroxyurea adherence among this 
population are needed. 
 
Introduction 
Sickle cell disease is a group of inherited red blood cell disorders predominately 
affecting minority populations in the US.
1,2
 There are numerous subtypes of sickle cell 
disease, the most severe of which is sickle cell anemia (SCA). SCA consists of the subtypes 
hemoglobin (Hb) SS and Hbβ0Thalassemia.2 Among children, SCA is associated with 
significant morbidity, the most common of which is recurrent pain.
2,3
 These pain crises 
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negatively impact the quality of life, as well as pose a significant burden of cost and 
utilization for the healthcare system.
4-6
  
Hydroxyurea is a medication that can reduce the incidence of pain crises through 
several pathways, including increasing the amount of fetal hemoglobin in the blood.
2,4,7-10
 
From 2002-2014, the National Heart, Lung, and Blood Institute (NHLBI) guidelines 
recommended hydroxyurea initiation among children and adolescents with specific 
indications, such as frequent pain episodes, history of acute chest syndrome, severe vaso-
occlusive events, or severe symptomatic anemia.
3
 However, revised guidelines released in 
2014 contain a different recommendation, stating that all children with SCA should be 
offered hydroxyurea therapy starting at 9 months of age. 
Despite the association between hydroxyurea therapy and improved clinical and 
economic outcomes, center-based and single-state reports of hydroxyurea use among children 
with SCA indicate low levels of use; at least half of children that met indication criteria did 
not receive this medication.
8,11-13
 However, little is known regarding hydroxyurea on a 
population-level or the extent to which use may vary over time.
8,14
 Therefore, the objective of 
this multistate study was to describe hydroxyurea use among children with SCA prior to 
release of the NHLBI revised guidelines. These findings establish a baseline by which to 
assess potential future changes in hydroxyurea use following the 2014 NHLBI guidelines, as 
comparable data become available. 
Methods 
Data Source 
Our target population was drawn from the Medicaid programs for the following 6 
states with an average to high prevalence of SCA: Florida, Illinois, Louisiana, Michigan, 
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South Carolina, and Texas. We selected a convenience sample of states due to completeness 
of data, availability of validation sources, and prevalence of SCA cases. Medicaid Analytic 
eXtract (MAX) administrative data were acquired from the Centers for Medicare and 
Medicaid Services (CMS) for 2005 to 2012; at the time of the study, this was the most recent 
complete data released by CMS. Administrative data included enrollment history and all paid 
claims for inpatient, outpatient, emergency department (ED), laboratory, and outpatient 
pharmacy services.  Approximately 90% of children with SCA are enrolled in Medicaid at 
some point in time and consequently, we expect Medicaid claims data captured a large 
proportion of the children with SCA in these states.
15
  
Study Population 
We identified children ages 1 through 17 years with SCA using a case definition of 
the presence of at least 3 claims for a child within a calendar year that were SCA-related 
(ICD-9-CM codes 282.61, 282.62). This case definition, targeted to specifically identify 
children with the subtype SCA, was previously demonstrated to have a high sensitivity (91%) 
and specificity (80%) as compared with the gold standard of newborn screening records.
16 
 
Continuous enrollment in the Medicaid program for at least 1 calendar year within this time 
period was required; children could contribute multiple, non-sequential time intervals (i.e., 
2009 and 2012). We restricted our analysis to children with no other forms of health 
insurance during the study period to maximize the completeness of Medicaid claims included 
in this analysis.  
Identifying Hydroxyurea Use 
To identify all pharmacy claims for hydroxyurea, a list of National Drug Codes 
(NDCs) for hydroxyurea was generated and verified using RxNorm, a normalized naming 
system for all drugs produced and maintained by the National Library of Medicine.
17
 For 
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each person-year in the study population, the total days’ supply of hydroxyurea was 
calculated as the sum of the days’ supply of each filled prescription within a calendar year.  
During the timeframe of Medicaid data included in this study (2005-2012), 
hydroxyurea was recommended for children with specific indications.
3
 Therefore, only a 
subset of children with SCA would have been prescribed hydroxyurea based on this 
recommendation. We used more than 30 filled days’ supply of hydroxyurea as a proxy for an 
indication for hydroxyurea prescription. More than 30 days’ supply is referred to as 
hydroxyurea use for the remainder of the manuscript.  Among children with hydroxyurea use, 
we assessed the proportion of children with at least 300 days of hydroxyurea. A threshold of 
300 days’ supply of medication in a calendar year is commonly applied in quality 
measurement, as it reflects a majority of the year of coverage, without requiring perfect 
adherence..
16
  
Statistical Analysis  
Frequencies and percentages or means and standard deviations (SDs) were determined 
for all demographics. The total number of days’ supply of hydroxyurea for each contributed 
person-year was calculated. Summary statistics of days’ supply of hydroxyurea were 
assessed. Among those with hydroxyurea use (person-years with evidence of more than 30 
days’ supply), the proportion of children that received at least 300 days’ supply was 
calculated by each year and state. To assess potential predictors of receiving at least 300 
days’ supply, a logistic regression model with generalized estimating equations to account for 
children contributing multiple time intervals was conducted among hydroxyurea users. This 
model estimated the association between potential predictors (age, sex, inpatient visits, 
outpatient visits, and emergency department visits) and receiving at least 300 days’ supply of 
hydroxyurea, adjusted for year and state.   
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Results 
A total of 7963 children with SCA ages 1 through 17 years of age were identified 
from 2005 to 2012, contributing a total of 22,424 person-years; less than 1% were excluded 
due to other forms of health insurance.  The number of person-years varied by state as 
follows: Florida (6816, 30%), Louisiana (3753, 17%), Texas (3727, 17%), Illinois (3298, 
15%), Michigan (2708, 12%), and South Carolina (2122, 9%).  Overall, the study population 
was 48% female (n = 3858); in 2005, the average age was 8.8 years (SD = 5.3), which was 
consistent across each year of observation.  The median age was 8 years in Florida, 
Louisiana, and Texas, and 9 years in Illinois, Michigan, and South Carolina.   
Among all person-years, 17,457 (77.9%) had 0 days of hydroxyurea within a year, 
597 (2.7%) had 1-30 days of hydroxyurea supply within a year, and 4370 (19.5%) were 
classified as having hydroxyurea use (>30 days of hydroxyurea supply within a year). Among 
person-years with hydroxyurea use, the average number of annual days’ supply was 189 
(SD=107.7). The annual proportion of those with hydroxyurea use who had at least 300 days’ 
supply ranged between 14.9% (2009) and 19.6% (2005) (Figure 1). 
Among those with hydroxyurea use, having at least 300 days’ supply of hydroxyurea 
was associated with age, inpatient admissions, and outpatient visits. Each increasing year of 
age and each additional inpatient admission were associated with lower odds. Conversely, 
more outpatient visits were associated with higher odds of having at least 300 days’ supply of 
hydroxyurea (Table 1). 
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Discussion 
In this multistate analysis, we established a baseline of hydroxyurea use, which can be 
used to assess improvements in hydroxyurea use following introduction of the new NHLBI 
guidelines. Our study indicated that hydroxyurea use among children with SCA was low 
across all years and states. Among children with evidence of hydroxyurea use, only one in 
five person-years received more than 300 days of hydroxyurea within a calendar year. This 
suggests that even among children that use hydroxyurea, medication adherence is low and 
strategies to increase adherence to hydroxyurea therapy among children with SCA are 
critically needed. These findings establish a baseline by which to assess potential future 
improvements in hydroxyurea following the release of the 2014 NHLBI guidelines.
7
   
The subsequent impacts of the revised NHLBI pediatric guidelines on hydroxyurea 
use among children with SCA are not well understood and should be evaluated. For example, 
the impact of the updated guidelines on physician behavior, such as anticipatory guidance and 
prescribing behaviors, should be assessed. Changes in caregiver and patient perspective, 
acceptance, and knowledge regarding hydroxyurea should also be assessed for changes 
following implementation of the revised guidelines.  
This study has several limitations.  It is possible that rates of hydroxyurea prescribing 
by providers to children with SCA are higher than the rates reported here, since medication 
claims reflect only those prescriptions that were actually filled as opposed to prescribed.  In 
addition, we did not assess which children within the study population met the NHLBI 
clinical indicators for hydroxyurea use; as a proxy, we included children with more than 30 
days’ supply as our denominator population. Finally, our results are limited by the accuracy 
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and completeness of administrative datasets, which may affect both the identification of the 
study population as well as measurement of the outcome of interest. 
In conclusion, even among children that are already using hydroxyurea, adherence 
rates are suboptimal. Given the NHLBI updated recommendations that all children with SCA 
should begin hydroxyurea therapy, it is critical that strategies to increase both initiation and 
adherence to hydroxyurea be developed and tested among this vulnerable population. 
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Table 1. Multivariable model predicting receipt of at least 300 days of hydroxyurea 
among children with SCA with evidence of hydroxyurea use (N=4370 person-years). 
Predictor Odds Ratio 95% Confidence Interval P-Value 
Inpatient Visits 0.77 0.73, 0.81 <0.0001 
ED Visits 1.01 0.99, 1.04 0.1982 
Outpatient Visits 1.01 1.00, 1.02 0.0018 
Age 0.93 0.91, 0.94 <0.0001 
Sex 
  
 
 
Male Reference Reference Reference 
 
Female 0.92 0.78, 1.08 0.2803 
State 
  
 
 
Illinois Reference Reference Reference 
 
Michigan 1.12 0.83, 1.50 0.4635 
 
Louisiana 0.93 0.71, 1.24 0.6339 
 
South Carolina 0.55 0.39, 0.79 0.0010 
 
Texas 0.78 0.59, 1.03 0.0754 
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Florida 0.96 0.74, 1.24 0.7567 
Year 
  
 
 
2005 Reference Reference Reference 
 
2006 0.85 0.59, 1.22 0.3861 
 
2007 0.90 0.63, 1.29 0.5669 
 
2008 0.93 0.65, 1.32 0.6683 
 
2009 0.67 0.47, 0.97 0.0311 
 
2010 0.80 0.57, 1.12 0.1944 
 
2011 0.69 0.49, 0.96 0.0273 
 
2012 0.64 0.46, 0.89 0.0076 
 
 
 
Figure 1. Proportion of children with at least 300 filled days of hydroxyurea among those 
with hydroxyurea use (greater than 30 days hydroxyurea medication filled) 
 
 
 
